ACE and Hypertension: In the 5.5-year trial, which included 15,257 patients with hypertension and at least three other cardiovascular disease risk factors, treatment with the calcium channel blocker (CCB) amlodipine (with or without the ACE inhibitor perindopril) was associated with a 16% reduction in risk of cardiovascular disease events and a 30% reduction in risk of new-onset diabetes compared with treatment with atenolol (± bendroflumethiazide) (39).